A. J. Garber

4.4k total citations
58 papers, 3.4k citations indexed

About

A. J. Garber is a scholar working on Endocrinology, Diabetes and Metabolism, Molecular Biology and Physiology. According to data from OpenAlex, A. J. Garber has authored 58 papers receiving a total of 3.4k indexed citations (citations by other indexed papers that have themselves been cited), including 39 papers in Endocrinology, Diabetes and Metabolism, 26 papers in Molecular Biology and 15 papers in Physiology. Recurrent topics in A. J. Garber's work include Diabetes Treatment and Management (33 papers), Metabolism, Diabetes, and Cancer (20 papers) and Diabetes Management and Research (19 papers). A. J. Garber is often cited by papers focused on Diabetes Treatment and Management (33 papers), Metabolism, Diabetes, and Cancer (20 papers) and Diabetes Management and Research (19 papers). A. J. Garber collaborates with scholars based in United States, Denmark and Italy. A. J. Garber's co-authors include David Kipnis, Irene E. Karl, Michelle A. Baron, Erika Rochotte, S. Dejager, Morey W. Haymond, Philip E. Cryer, Anja Schweizer, Julio V. Santiago and Anthony S. Pagliara and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Investigation and American Journal of Clinical Nutrition.

In The Last Decade

A. J. Garber

57 papers receiving 3.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
A. J. Garber United States 26 2.1k 1.2k 854 748 423 58 3.4k
Pierre J. Lefèbvre Belgium 32 1.8k 0.9× 779 0.7× 972 1.1× 1.0k 1.4× 274 0.6× 144 3.7k
J. Radziuk Canada 26 1.1k 0.5× 950 0.8× 874 1.0× 739 1.0× 290 0.7× 76 2.7k
John M. Amatruda United States 41 2.5k 1.2× 1.7k 1.4× 1.2k 1.4× 1.2k 1.6× 359 0.8× 84 4.6k
Edward S. Horton United States 32 1.5k 0.7× 1.8k 1.5× 1.7k 2.0× 640 0.9× 892 2.1× 58 4.1k
S. Matthäei Germany 29 1.5k 0.7× 1.4k 1.2× 1.2k 1.4× 835 1.1× 305 0.7× 84 3.7k
N. Nurjhan United States 27 1.2k 0.6× 1.3k 1.1× 1.5k 1.8× 698 0.9× 579 1.4× 40 3.3k
Katsuyuki Ando Japan 36 1.3k 0.6× 1.2k 1.0× 887 1.0× 723 1.0× 184 0.4× 128 4.6k
Kazunori Utsunomiya Japan 32 1.6k 0.8× 1.3k 1.1× 582 0.7× 807 1.1× 126 0.3× 152 4.0k
Ole Schmitz Denmark 29 2.3k 1.1× 1.5k 1.3× 751 0.9× 1.5k 2.0× 204 0.5× 57 3.6k
K. Rett Germany 28 987 0.5× 858 0.7× 1.4k 1.7× 332 0.4× 383 0.9× 83 3.4k

Countries citing papers authored by A. J. Garber

Since Specialization
Citations

This map shows the geographic impact of A. J. Garber's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by A. J. Garber with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites A. J. Garber more than expected).

Fields of papers citing papers by A. J. Garber

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by A. J. Garber. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by A. J. Garber. The network helps show where A. J. Garber may publish in the future.

Co-authorship network of co-authors of A. J. Garber

This figure shows the co-authorship network connecting the top 25 collaborators of A. J. Garber. A scholar is included among the top collaborators of A. J. Garber based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with A. J. Garber. A. J. Garber is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Philis‐Tsimikas, Athena, Stefano Del Prato, İlhan Satman, et al.. (2013). Effect of insulin degludec versus sitagliptin in patients with type 2 diabetes uncontrolled on oral antidiabetic agents. Diabetes Obesity and Metabolism. 15(8). 760–766. 31 indexed citations
2.
Garber, A. J.. (2011). Obesity and type 2 diabetes: which patients are at risk?. Diabetes Obesity and Metabolism. 14(5). 399–408. 83 indexed citations
3.
4.
Garber, A. J.. (2009). Restaging insulin therapy for patients with type 2 diabetes. Diabetes Obesity and Metabolism. 11(s5). 1–5. 6 indexed citations
5.
Jendle, Johan, Michael A. Nauck, David R. Matthews, et al.. (2009). Weight loss with liraglutide, a once‐daily human glucagon‐like peptide‐1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue. Diabetes Obesity and Metabolism. 11(12). 1163–1172. 247 indexed citations
6.
Plutzky, Jorge, et al.. (2009). Reductions in lipids and CV risk markers in patients with type 2 diabetes treated with liraglutide: a meta-analysis. Canadian Journal of Diabetes. 33(3). 209–210. 27 indexed citations
7.
Jendle, Johan, Michael A. Nauck, D. M. Matthews, et al.. (2008). The reduction of body weight with liraglutide, a once-daily human GLP-I analogue for type 2 diabetes, primarily comes from fat tissue and the fat tissue lost is predominantly visceral fat. Lund University Publications (Lund University). 3 indexed citations
8.
9.
Garber, A. J., Anja Schweizer, Michelle A. Baron, Erika Rochotte, & S. Dejager. (2006). Vildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: a randomized, placebo‐controlled study*. Diabetes Obesity and Metabolism. 9(2). 166–174. 241 indexed citations
10.
Ray, Joshua, William J. Valentine, S Roze, et al.. (2006). Insulin therapy in type 2 diabetes patients failing oral agents: cost‐effectiveness of biphasic insulin aspart 70/30 vs. insulin glargine in the US*. Diabetes Obesity and Metabolism. 9(1). 103–113. 23 indexed citations
11.
Rosenstock, Julio, et al.. (2006). Improvement in glycaemic control with rosiglitazone/metformin fixed‐dose combination therapy in patients with type 2 diabetes with very poor glycaemic control. Diabetes Obesity and Metabolism. 8(6). 643–649. 30 indexed citations
12.
Garber, A. J., E. Klein, Simon Bruce, Serap Sankoh, & Pharis Mohideen. (2005). Metformin‐glibenclamide versus metformin plus rosiglitazone in patients with type 2 diabetes inadequately controlled on metformin monotherapy. Diabetes Obesity and Metabolism. 8(2). 156–163. 62 indexed citations
13.
Garber, A. J.. (2003). Metformin and vascular protection: a diabetologist's view. Diabetes & Metabolism. 29(4). 6S113–6S116. 4 indexed citations
14.
15.
Hong, Sook Hee, et al.. (2002). Fenofibrate lowers abdominal and skeletal adiposity and improves insulin sensitivity in OLETF rats. Biochemical and Biophysical Research Communications. 296(2). 293–299. 96 indexed citations
16.
Garber, A. J., et al.. (2002). Simultaneous glyburide/metformin therapy is superior to component monotherapy as an initial pharmacological treatment for type 2 diabetes. Diabetes Obesity and Metabolism. 4(3). 201–208. 104 indexed citations
17.
Garber, A. J.. (2000). Implications of cardiovascular risk in patients with type 2 diabetes who have abnormal lipid profiles: is lower enough?. Diabetes Obesity and Metabolism. 2(5). 263–270. 3 indexed citations
18.
Garber, A. J.. (1996). Magnesium utilization survey in selected patients with diabetes. Clinical Therapeutics. 18(2). 285–294. 4 indexed citations
19.
Jankovic, Joseph, Robert Grossman, Carl B. Goodman, et al.. (1989). Clinical, biochemical, and neuropathologic findings following transplantation of adrenal medulla to the caudate nucleus for treatment of Parkinson's disease. Neurology. 39(9). 1227–1227. 73 indexed citations
20.
Garber, A. J., Philip Cryer, & Julio V. Santiago. (1975). Substrate and hormonal responses to hypoglycemia in man. Diabetes. 24. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Pierre J. Lefèbvre Breakdown of academic impact, for papers by J. Radziuk Breakdown of academic impact, for papers by John M. Amatruda Breakdown of academic impact, for papers by Edward S. Horton Breakdown of academic impact, for papers by S. Matthäei Breakdown of academic impact, for papers by N. Nurjhan Breakdown of academic impact, for papers by Katsuyuki Ando Breakdown of academic impact, for papers by Kazunori Utsunomiya Breakdown of academic impact, for papers by Ole Schmitz Breakdown of academic impact, for papers by K. Rett
Rankless by CCL
2026